Skip to main content

Alkermes PLC (ALKS)

NASDAQ: ALKS · IEX Real-Time Price · USD
31.67 -0.18 (-0.57%)
Oct 15, 2021 4:00 PM EDT - Market closed
Market Cap5.21B
Revenue (ttm)1.10B
Net Income (ttm)-62.83M
Shares Out160.82M
EPS (ttm)-0.40
PE Ration/a
Forward PE588.24
Dividendn/a
Ex-Dividend Daten/a
Volume2,441,914
Open32.26
Previous Close31.85
Day's Range31.65 - 32.38
52-Week Range15.35 - 33.00
Beta0.95
AnalystsHold
Price Target28.13 (-11.2%)
Est. Earnings DateOct 28, 2021

About ALKS

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizop...

IndustryBiotechnology
IPO DateJul 16, 1991
Employees2,245
Stock ExchangeNASDAQ
Ticker SymbolALKS
Full Company Profile

Financial Performance

In 2020, Alkermes's revenue was $1.04 billion, a decrease of -11.29% compared to the previous year's $1.17 billion. Losses were -$110.86 million, -43.62% less than in 2019.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for Alkermes stock is "Hold." The 12-month stock price forecast is 28.13, which is a decrease of -11.18% from the latest price.

Price Target
$28.13
(-11.18% downside)
Analyst Consensus: Hold

News

Top Ranked Momentum Stocks to Buy for October 13th

ALKS, BP, and E made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 13, 2021.

Other symbols:BPE
2 days ago - Zacks Investment Research

2 Supercharged Stocks Near 52-Week Highs Despite the Market Pullback

Are they stocks to buy near the highs?

Other symbols:BAC
3 days ago - The Motley Fool

Find 'Strong Buy' Stocks for October and Beyond with this Screener

Given this backdrop, investors with long-term horizons should remain on the hunt for stocks because timing the market is difficult. Utilizing our Filtered Zacks Rank 5 Stock Screener is a great place to...

Other symbols:JPMSB
3 days ago - Zacks Investment Research

Alkermes to Take Part in the Cantor Virtual Global Healthcare Conference

DUBLIN, Sept. 22, 2021 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Wednesday, S...

3 weeks ago - PRNewsWire

New Survey Provides Insights Into Drinking Behaviors During the Pandemic

DUBLIN, Sept. 22, 2021 /PRNewswire/ -- A new online survey conducted during the COVID-19 pandemic by The Harris Poll on behalf of Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), found that ...

3 weeks ago - PRNewsWire

Alkermes to Present Two Posters on Investigational Immuno-oncology Candidate, Nemvaleukin Alfa, at the 2021 European ...

DUBLIN, Sept. 13, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced two poster presentations related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered in...

1 month ago - PRNewsWire

Alkermes Announces Launch of 4th Annual Alkermes Pathways Research Awards® Program

DUBLIN, Sept. 9, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Sept.

1 month ago - PRNewsWire

Alkermes to Take Part in the Citi Annual BioPharma Virtual Conference

DUBLIN, Sept. 2, 2021 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Citi 16th Annual BioPharma Virtual Conference on Thursday, S...

1 month ago - PRNewsWire

BofA Downgrades Alkermes After Stock Rally: 'We Don't See A Favorable Catalyst Pathway'

Following the recent rally, Alkermes Plc's (NASDAQ:ALKS) shares have exceeded their fair value and the stock looks “expensive on a relative basis,” according to BofA Securities. The Alkermes Analyst: Ja...

1 month ago - Benzinga

What's Next For Alkermes Stock After A 16% Rise Last Month?

The stock price of Alkermes, a biopharmaceutical company focused on neuroscience and oncology, has seen a rise of around 16% over the last twenty-one trading days, and it is up a solid 91% over the last...

1 month ago - Forbes

Alkermes' (ALKS) Drug Portfolio Aids Growth, High Reliance a Woe

Alkermes' (ALKS) portfolio of proprietary products drives growth while its pipeline progress has been impressive. However, heavy dependence on partners for royalty revenues remains a concern.

1 month ago - Zacks Investment Research

Why Is Alkermes (ALKS) Up 19.4% Since Last Earnings Report?

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Alkermes Receives FDA Fast Track Status For Mucosal Melanoma Immunotherapy

The FDA has granted Fast Track designation to Alkermes plc's (NASDAQ: ALKS) nemvaleukin alfa (nemvaleukin) for mucosal melanoma. Nemvaleukin is an investigational engineered interleukin-2 (IL-2) variant...

2 months ago - Benzinga

Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma

DUBLIN, Aug. 2, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nemvaleukin alfa (nemvaleukin), th...

2 months ago - PRNewsWire

Alkermes (ALKS) Beats on Q2 Earnings & Sales, Ups '21 View

Following a positive recovery from COVID-impacts, Alkermes (ALKS) beat both earnings and sales estimates in second-quarter 2021. The company also raised its guidance for 2021.

2 months ago - Zacks Investment Research

Alkermes (ALKS) Q2 Earnings and Revenues Beat Estimates

Alkermes (ALKS) delivered earnings and revenue surprises of 150.00% and 9.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Alkermes: Q2 Earnings Insights

Shares of Alkermes (NASDAQ:ALKS) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share rose 400.00% over the past year to $0.30, which beat the estimate of $0.12.

2 months ago - Benzinga

Alkermes plc Reports Second Quarter 2021 Financial Results

DUBLIN, July 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2021 and provided updated financial expectations for full-year 2021. "Alkerme...

2 months ago - PRNewsWire

Alkermes Announces Recipients of 2021 Alkermes Inspiration Grants® Program

DUBLIN, July 23, 2021 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today announced the 2021 recipients of grants from the company's signature Alkermes Inspiration Grants® program. Grants were awarded to...

2 months ago - PRNewsWire

Alkermes to Report Second Quarter 2021 Financial Results on July 28, 2021

DUBLIN, July 21, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.

2 months ago - PRNewsWire

7 Growth Stocks to Buy As Meme Stock Mania Fades

As the craze for meme stocks fades away, investors should consider growth investing to generate big returns. Here are 7 growth stocks to buy today.

Other symbols:ATRPEXLRMDSMPTPXVIOG
2 months ago - InvestorPlace

Alkermes Presented New Data Analysis on Healthcare Resource Use Among Veterans With Alcohol Dependence

DUBLIN, June 30, 2021 /PRNewswire/ --  Alkermes plc  (Nasdaq: ALKS) today announced the presentation of new health economics and outcomes research related to healthcare resource use (HRU) among veterans...

3 months ago - PRNewsWire

Alkermes Announces Former Professional Baseball Player, CC Sabathia, as Spokesperson for Alcohol Dependence Awareness...

DUBLIN, June 22, 2021 /PRNewswire/ -- Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), today announced former professional baseball player and World Series champion, CC Sabathia, as a spokes...

3 months ago - PRNewsWire

Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs

Biogen isn't the only company whose shares should benefit from a breakthrough drug.

Other symbols:ALPN
4 months ago - The Motley Fool

Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting

DUBLIN, June 4, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from its ARTISTRY clinical development program for nemvaleukin alfa (nemvaleukin), Alkermes' novel, investigatio...

4 months ago - PRNewsWire